CRISPR Therapeutics develops gene-edited medicines using CRISPR/Cas9 technology. Its flagship therapy, CASGEVY (exagamglogene autotemcel), developed with Vertex Pharmaceuticals, is approved for sickle cell disease and transfusion-dependent beta-thalassemia. The pipeline also targets immuno-oncology and regenerative medicine, positioning the firm among the leaders in clinical gene editing.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -136 | — |
| Q2 2025 | 0 | — | -208.6 | — |
| Q3 2025 | 0 | — | -106.4 | — |
| Q4 2025 | 0 | — | -130.6 | — |
| Q1 2026 | 1 | — | -122.9 | — |
| Q2 2026 | 10 | — | -91.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Regencell Bioscience Holdings Limited (RGC), Icahn Enterprises L.P. (IEP), Insight Enterprises, Inc. (NSIT), Construction Partners, Inc. (ROAD), Dave Inc. (DAVE), Erasca, Inc. (ERAS)